An In Vivo Model of Human Macrophages in Metastatic Melanoma.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 08 2022
Historique:
received: 29 11 2021
accepted: 26 05 2022
pubmed: 12 7 2022
medline: 2 8 2022
entrez: 11 7 2022
Statut: ppublish

Résumé

Despite recent therapeutic progress, advanced melanoma remains lethal for many patients. The composition of the immune tumor microenvironment (TME) has decisive impacts on therapy response and disease outcome, and high-dimensional analyses of patient samples reveal the heterogeneity of the immune TME. Macrophages infiltrate TMEs and generally associate with tumor progression, but the underlying mechanisms are incompletely understood. Because experimental systems are needed to elucidate the functional properties of these cells, we developed a humanized mouse model reconstituted with human immune cells and human melanoma. We used two strains of recipient mice, supporting or not supporting the development of human myeloid cells. We found that human myeloid cells favored metastatic spread of the primary tumor, thereby recapitulating the cancer-supportive role of macrophages. We next analyzed the transcriptome of human immune cells infiltrating tumors versus other tissues. This analysis identified a cluster of myeloid cells present in the TME, but not in other tissues, which do not correspond to canonical M2 cells. The transcriptome of these cells is characterized by high expression of glycolytic enzymes and multiple chemokines and by low expression of gene sets associated with inflammation and adaptive immunity. Compared with humanized mouse results, we found transcriptionally similar myeloid cells in patient-derived samples of melanoma and other cancer types. The humanized mouse model described here thus complements patient sample analyses, enabling further elucidation of fundamental principles in melanoma biology beyond M1/M2 macrophage polarization. The model can also support the development and evaluation of candidate antitumor therapies.

Identifiants

pubmed: 35817516
pii: jimmunol.2101109
doi: 10.4049/jimmunol.2101109
pmc: PMC9377377
mid: NIHMS1813806
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

606-620

Subventions

Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234720
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA080416
Pays : United States

Informations de copyright

Copyright © 2022 by The American Association of Immunologists, Inc.

Références

Cell. 2021 Feb 4;184(3):792-809.e23
pubmed: 33545035
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Nat Immunol. 2014 Feb;15(2):195-204
pubmed: 24336226
Cell. 2014 Dec 4;159(6):1312-26
pubmed: 25480296
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
Nature. 2015 Jan 15;517(7534):381-5
pubmed: 25561180
Cancer Cell. 2021 May 10;39(5):610-631
pubmed: 33545064
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Nature. 2019 Feb;566(7745):496-502
pubmed: 30787437
Trends Mol Med. 2018 May;24(5):472-489
pubmed: 29655673
Nat Immunol. 2016 Jan;17(1):9-17
pubmed: 26681457
J Exp Med. 2001 Mar 19;193(6):727-40
pubmed: 11257139
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Nat Biotechnol. 2014 Apr;32(4):364-72
pubmed: 24633240
Cell. 2014 Dec 4;159(6):1327-40
pubmed: 25480297
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Nat Methods. 2018 Aug;15(8):623-630
pubmed: 30065364
Front Immunol. 2015 Jun 25;6:330
pubmed: 26124761
Methods Mol Biol. 2016;1423:309-20
pubmed: 27142026
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Cell Rep. 2017 Nov 14;21(7):1953-1967
pubmed: 29141225
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Annu Rev Immunol. 2019 Apr 26;37:269-293
pubmed: 30649988
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
J Clin Oncol. 2009 Jul 10;27(20):3330-7
pubmed: 19528371
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Nat Rev Immunol. 2014 Aug;14(8):571-8
pubmed: 25033907
Cell. 2019 Oct 31;179(4):829-845.e20
pubmed: 31675496
Front Immunol. 2021 Feb 22;12:643852
pubmed: 33692812
Science. 2004 Apr 2;304(5667):104-7
pubmed: 15064419
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Pathol. 2002 Mar;196(3):254-65
pubmed: 11857487
Blood Adv. 2019 Feb 12;3(3):268-274
pubmed: 30696625
J Immunol. 1998 Feb 15;160(4):1750-8
pubmed: 9469433
Genome Biol. 2018 Dec 3;19(1):211
pubmed: 30509292
Nat Immunol. 2016 Jan;17(1):34-40
pubmed: 26681460
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Nat Rev Cancer. 2017 Apr;17(4):254-268
pubmed: 28104906
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Annu Rev Immunol. 2013;31:635-674
pubmed: 23330956
Cancer Res. 2004 Oct 1;64(19):7022-9
pubmed: 15466195
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Genome Biol. 2015 Dec 10;16:278
pubmed: 26653891
Trends Immunol. 2011 Jul;32(7):321-7
pubmed: 21697012
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734
Nat Genet. 2009 May;41(5):544-52
pubmed: 19282848
Nat Rev Dis Primers. 2015 Apr 23;1:15003
pubmed: 27188223
Trends Immunol. 2011 Jan;32(1):19-25
pubmed: 21067974

Auteurs

Valentin Voillet (V)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
Cape Town HIV Vaccine Trials Network Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.

Trisha R Berger (TR)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

Kelly M McKenna (KM)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Graduate Program in Molecular and Cellular Biology, University of Washington, Seattle, WA.
Medical Scientist Training Program, University of Washington, Seattle, WA.

Kelly G Paulson (KG)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

Wei Hong Tan (WH)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

Kimberly S Smythe (KS)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

Daniel S Hunter (DS)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

William J Valente (WJ)

Graduate Program in Molecular and Cellular Biology, University of Washington, Seattle, WA.
Medical Scientist Training Program, University of Washington, Seattle, WA.
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA.

Stephanie Weaver (S)

Experimental Histopathology, Fred Hutchinson Cancer Center, Seattle, WA.

Jean S Campbell (JS)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA.

Teresa S Kim (TS)

Department of Surgery, University of Washington, Seattle, WA.

David R Byrd (DR)

Department of Surgery, University of Washington, Seattle, WA.

Jason H Bielas (JH)

Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA.
Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA.

Robert H Pierce (RH)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

Aude G Chapuis (AG)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Department of Medicine, University of Washington, Seattle, WA.

Raphaël Gottardo (R)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
Department of Biostatistics, University of Washington, Seattle, WA; and.

Anthony Rongvaux (A)

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; rongvaux@fredhutch.org.
Department of Immunology, University of Washington, Seattle, WA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH